Related Experiment Video

Updated: May 8, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

[Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?]

J Lüdemann1

  • 1mail@Diabetes-Falkensee.de

MMW Fortschritte Der Medizin
|August 23, 2013
PubMed

Insights

Intensive glycemic control in type 2 diabetes may cause severe hypoglycemia and weight gain. Modern treatments should focus on early, sustained blood sugar reduction while preventing these side effects, especially with new GLP-1 receptor agonists.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) guideline therapy targeting HbA1c < 6.5% is questioned by recent studies (ACCORD, ADVANCE, VADT).
  • Intensive glycemic control is associated with increased risks of severe hypoglycemia and weight gain.
  • Current treatment paradigms require re-evaluation to balance efficacy with safety and patient-centered outcomes.

Purpose of the Study:

  • To review current treatment options for T2DM based on modern therapeutic requirements.
  • To evaluate strategies for early and sustained glycemic control.
  • To assess methods for preventing hypoglycemia and weight gain in T2DM management, with a focus on GLP-1 receptor agonists.

Main Methods:

  • Review of recent clinical studies and guidelines concerning T2DM management.
  • Analysis of therapeutic options considering early intervention, sustained glycemic control, and adverse event prevention.
  • Specific focus on the role and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists.

Main Results:

  • Intensive glycemic control may not always be beneficial due to risks like severe hypoglycemia and weight gain.
  • Modern T2DM treatment should prioritize early initiation, sustained glucose reduction, and simultaneous prevention of adverse effects.
  • GLP-1 receptor agonists show promise in meeting these modern treatment criteria.

Conclusions:

  • Current T2DM guidelines targeting strict HbA1c levels need careful consideration regarding potential harms.
  • A shift towards comprehensive treatment strategies that include early intervention and side effect management is necessary.
  • GLP-1 receptor agonists represent a valuable therapeutic class for achieving modern treatment goals in T2DM.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...